We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+0.81%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$328M
AUM Growth
-$55.1M
Cap. Flow
-$44.7M
Cap. Flow %
-13.62%
Top 10 Hldgs %
42.21%
Holding
136
New
34
Increased
27
Reduced
16
Closed
41

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$14.8M
2
SLNO
Soleno Therapeutics
SLNO
+$14.3M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.24M
4
TGTX icon
TG Therapeutics
TGTX
+$6.09M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$4.61M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.5M
2
ARGX icon
argenx
ARGX
+$3.66M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.54M
4
LLY icon
Eli Lilly
LLY
+$3.49M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 49.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVPH
51
CALL
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$1.52M 0.46%
+200,000
New +$3.11M
QURE icon
52
CALL
uniQure
QURE
$3.03B
$1.45M 0.44%
104,100
-50,000
-32% -$673K
COGT icon
53
PUT
Cogent Biosciences
COGT
$6.65B
$1.45M 0.44%
201,400
– –
BHVN icon
54
CALL
Biohaven
BHVN
$2.03B
$1.41M 0.43%
+100,000
New +$1.78M
PCRX icon
55
Pacira BioSciences
PCRX
$1.04B
$1.41M 0.43%
58,926
+20,000
+51% +$504K
OCUL icon
56
CALL
Ocular Therapeutix
OCUL
$1.79B
$1.27M 0.39%
136,700
– –
OLMA icon
57
Olema Pharmaceuticals
OLMA
$1B
$1.08M 0.33%
253,657
+153,657
+154% +$685K
SMMT icon
58
PUT
Summit Therapeutics
SMMT
$10.4B
$1.06M 0.32%
+50,000
New +$1.14M
CAPR icon
59
PUT
Capricor Therapeutics
CAPR
$223M
$1.06M 0.32%
+106,600
New +$1.13M
RVPH
60
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$1.04M 0.32%
136,773
+104,237
+320% +$1.62M
DFTX
61
Definium Therapeutics
DFTX
$5.78B
$1.03M 0.31%
+158,536
New +$1.04M
BMEA icon
62
CALL
Biomea Fusion
BMEA
$84.6M
$1.02M 0.31%
+568,900
New +$1.1M
TNGX icon
63
CALL
Tango Therapeutics
TNGX
$4.43B
$1.02M 0.31%
+200,000
New +$495K
TRVI icon
64
Trevi Therapeutics
TRVI
$2.59B
$1.02M 0.31%
185,830
+5,830
+3% +$36.3K
GOSS icon
65
CALL
Gossamer Bio
GOSS
$82.9M
$1.01M 0.31%
824,800
– –
TERN
66
DELISTED
Terns Pharmaceuticals
TERN
$969K 0.3%
259,852
+203,754
+363% +$636K
ETNB
67
DELISTED
89bio
ETNB
$966K 0.29%
98,382
-133,054
-57% -$1.1M
SLS icon
68
CALL
SELLAS Life Sciences
SLS
$1.97B
$876K 0.27%
+400,000
New +$614K
CLYM
69
Climb Bio
CLYM
$681M
$871K 0.27%
702,135
+32,332
+5% +$40.2K
SCPH
70
DELISTED
scPharmaceuticals
SCPH
$829K 0.25%
+217,623
New +$676K
VTGN icon
71
VistaGen Therapeutics
VTGN
$9.89M
$808K 0.25%
403,922
-162,053
-29% -$368K
FOLD
72
CALL
DELISTED
Amicus Therapeutics
FOLD
$753K 0.23%
131,400
– –
ARVN icon
73
Arvinas
ARVN
$518M
$710K 0.22%
+96,455
New +$710K
ALT icon
74
PUT
Altimmune
ALT
$552M
$663K 0.2%
+171,400
New +$928K
CRDF icon
75
CALL
Cardiff Oncology
CRDF
$66.5M
$656K 0.2%
208,100
– –
1 2
3
4 5

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Diadema Partners held 136 positions worth $328M, down 14% from $383M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Diadema Partners withdrew a net $44.7M in Q2 2025, closing 41 positions and reducing 16 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $3.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 33% a quarter earlier.

Against the trend, Diadema Partners opened a new position in Amgen worth $14.5M.

  • Diadema Partners's largest Q2 2025 buy was Amgen: 52,100 shares worth $14.5M.
  • Diadema Partners added most to Soleno Therapeutics in Q2 2025, an estimated $14.3M increase.
  • Diadema Partners's biggest Q2 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
  • Diadema Partners fully exited Alnylam Pharmaceuticals in Q2 2025, selling an estimated $3.54M.
  • Diadema Partners's ten largest holdings make up 42% of its $328M portfolio in Q2 2025.
  • Diadema Partners opened 34 new positions and closed 41 in Q2 2025.
  • Diadema Partners's portfolio value fell 14% quarter-over-quarter to $328M.

Based on Diadema Partners's 13F filing for Q2 2025, filed 14 Aug 2025.